ArticleJournal of oral and maxillofacial pathology : JOMFP
Osteogenic effects of metformin and exenatide on bone regeneration in non-diabetic rats: A Micro-CT and histological study.
Article in Journal of oral and maxillofacial pathology : JOMFP. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: This study aimed to evaluate the osteogenic effects of systemic metformin and exenatide administration on bone tissue regeneration in an experimental rat model by utilising micro-computed tomography (micro-CT) and histological analysis. Materials and Methods: Uniform craniotomy defects measuring 3 mm in diameter and 2 mm depth were performed in the parietal bones of 27 female albino Wistar rats, which were randomly divided into three groups: 1) a group receiving 100 mg/kg/day of oral metformin, 2) a group receiving 3 μg/kg/day of intraperitoneal exenatide, and 3) a control group receiving no medication. Bone volume and density at the defect site were evaluated using micro-CT scanning and analysis. Results: Bone regeneration and the integration of newly formed bone into intact bone were assessed through histological and immunohistochemical examinations. In all three groups, the results showed no significant differences in bone volume, bone density, the presence of fibrous connective tissue, or the complete integration of the defect area into the bone tissue. However, the experimental groups exhibited significant differences in the number of osteoblasts ( Conclusions: Metformin and exenatide enhance the activity of osteoblasts and osteoclasts in bone defects, promoting osteogenic potential during the healing process in non-diabetic rats.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.